EHA 2022 | Antibodies in multiple myeloma and their impact on treatment
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses recent advances in the use of antibodies for the treatment of multiple myeloma, highlighting the promise of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), as well as bispecifics. Prof. Raje first comments on the movement of mAbs into the frontline setting and advances in quadruplet regimens. Following this, Prof. Raje highlights the DETERMINATION trial (NCT01208662), and further discusses the use of ADCs, such as belantamab mafodotin, as a single agent and in combination with other agents. To conclude, Prof. Raje discusses the promise of bispecific antibodies including teclistamab and elranatamab, and their place in the myeloma treatment landscape. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
